Now Is A Suitable Moment For A Long-Term Purchase Of UroGen Pharma Ltd (NASDAQ: URGN)
Currently, there are 30.81M common shares owned by the public and among those 26.83M shares have been available to trade. Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, […]
